Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT

MLA

Frances Humby, et al. “Rituximab versus Tocilizumab and B-Cell Status in TNF-Alpha Inadequate-Responder Rheumatoid Arthritis Patients: The R4-RA RCT.” Efficacy and Mechanism Evaluation, vol. 9, no. 7, Aug. 2022. EBSCOhost, https://doi.org/10.3310/GOPL1729.

APA

Frances Humby, Patrick Durez, Maya H Buch, Myles J Lewis, Michele Bombardieri, Christopher John, Hasan Rizvi, Louise Warren, Joanna Peel, Liliane Fossati-Jimack, Rebecca E Hands, Giovanni Giorli, Felice Rivellese, Juan D Cañete, Peter C Taylor, Peter Sasieni, João E Fonseca, Ernest Choy, & Costantino Pitzalis. (2022). Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT. Efficacy and Mechanism Evaluation, 9(7). https://doi.org/10.3310/GOPL1729

Chicago

Frances Humby, Patrick Durez, Maya H Buch, Myles J Lewis, Michele Bombardieri, Christopher John, Hasan Rizvi, et al. 2022. “Rituximab versus Tocilizumab and B-Cell Status in TNF-Alpha Inadequate-Responder Rheumatoid Arthritis Patients: The R4-RA RCT.” Efficacy and Mechanism Evaluation 9 (7). doi:10.3310/GOPL1729.